Tumor Immunotherapy Using A2A Adenosine Receptor Antagonists

被引：20
作者：
Zhang, Jinfeng [1 ,2 ]
Yan, Wenzhong [1 ]
Duan, Wenwen [1 ]
Wuthrich, Kurt [1 ,3 ]
Cheng, Jianjun [1 ]
机构：
[1] ShanghaiTech Univ, IHuman Inst, Shanghai 201210, Peoples R China
[2] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China
[3] Scripps Res, Dept Integrated Struct & Computat Biol, La Jolla, CA 92037 USA
来源：
PHARMACEUTICALS | 2020年 / 13卷 / 09期
关键词：
GPCR; immuno-oncology; Parkinson's disease; drug binding modes; cancer therapy; PARKINSONS-DISEASE; CRYSTAL-STRUCTURE; DERIVATIVES; ZM241385; POTENT; ZM-241385; BLOCKADE; BINDING; CELLS;
D O I：
10.3390/ph13090237
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
The A(2A) adenosine receptor (A(2A) AR) plays critical roles in human physiology and pathophysiology, which makes it an important drug target. Previous drug-discovery efforts targeting the A(2A) AR have been focused on the use of A(2A) AR antagonists for the treatment of Parkinson's disease. More recently, the A(2A) AR has attracted additional attention for its roles in immuno-oncology, and a number of A(2A) AR antagonists are currently used as lead compounds for antitumor drugs in both preclinical models and clinical trials. This review surveys recent advances in the development of A(2A) AR antagonists for cancer immunotherapy. The therapeutic potential of representative A(2A) AR antagonists is discussed based on both animal efficacy studies and clinical data.
引用
收藏
页码：1 / 14
页数：14
相关论文
共 50 条
  • [31] Structurally Enabled Discovery of Adenosine A2A Receptor Antagonists
    Jazayeri, Ali
    Andrews, Stephen P.
    Marshall, Fiona H.
    CHEMICAL REVIEWS, 2017, 117 (01) : 21 - 37
  • [32] Synthesis of alkyne derivatives of a novel triazolopyrazine as A2A adenosine receptor antagonists
    Yao, G
    Haque, S
    Sha, L
    Kumaravel, G
    Wang, J
    Engber, TM
    Whalley, ET
    Conlon, PR
    Chang, HX
    Kiesman, WF
    Petter, RC
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (03) : 511 - 515
  • [33] Novel investigational adenosine A2A receptor antagonists for Parkinson's disease
    Pinna, Annalisa
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (11) : 1619 - 1631
  • [34] Studies on adenosine A2a receptor antagonists:: comparison of three core heterocycles
    Vu, CB
    Pan, D
    Peng, B
    Sha, L
    Kumaravel, G
    Jin, XW
    Phadke, D
    Engber, T
    Huang, C
    Reilly, J
    Tam, S
    Petter, RC
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (19) : 4831 - 4834
  • [35] Adenosine, adenosine A2A antagonists, and Parkinson's disease
    Jenner, P.
    Mori, A.
    Hauser, R.
    Morelli, M.
    Fredholm, B. B.
    Chen, J. F.
    PARKINSONISM & RELATED DISORDERS, 2009, 15 (06) : 406 - 413
  • [36] Recent Advances in the In-silico Structure-based and Ligand-based Approaches for the Design and Discovery of Agonists and Antagonists of A2A Adenosine Receptor
    Agrawal, Nikhil
    Chandrasekaran, Balakumar
    Al-Aboudi, Amal
    CURRENT PHARMACEUTICAL DESIGN, 2019, 25 (07) : 774 - 782
  • [37] Pharmacophore mapping and in silico screening to identify new potent leads for A2A adenosine receptor as antagonists
    Mustyala, Kiran Kumar
    Chitturi, Annapurna Renee
    James, Prameela Subhashini Naikal
    Vuruputuri, Uma
    JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION, 2012, 32 (02) : 102 - 113
  • [38] Benzopyrone represents a privilege scaffold to identify novel adenosine A1/A2A receptor antagonists
    van der Walt, Mietha M.
    Terre'Blanche, Gisella
    BIOORGANIC CHEMISTRY, 2018, 77 : 136 - 143
  • [39] Adenosine A2a receptor antagonists attenuate striatal adaptations following dopamine depletion
    Peterson, Jayms D.
    Goldberg, Joshua A.
    Surmeier, D. James
    NEUROBIOLOGY OF DISEASE, 2012, 45 (01) : 409 - 416
  • [40] HQSAR and molecular docking studies of furanyl derivatives as adenosine A2A receptor antagonists
    Camila Muñoz-Gutiérrez
    Julio Caballero
    Alejandro Morales-Bayuelo
    Medicinal Chemistry Research, 2016, 25 : 1316 - 1328
12345